Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: August 23, 2017
Expiration Date: August 23, 2018

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Treatment paradigms for relapsed/refractory Hodgkin lymphoma (R/R HL) have evolved significantly with availability of brentuximab vedotin (BV) and nivolumab, providing alternative treatment options to cytotoxic chemotherapy. However, providers face challenges in the sequencing of drugs and selection of treatment based on patient- and disease-related factors. In this activity, participants will learn about treatment strategies and algorithms for selecting therapy in patients with R/R HL from Dr. John Sweetenham, who will also address the role of patient- and disease-related factors in treatment decisions, such as preexisting comorbidities, tolerability, and response to prior therapy.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Outline potential treatment strategies and therapeutic algorithms for drug selection and sequencing in patients with relapsed/refractory Hodgkin lymphoma (R/R HL)
  • Differentiate between therapies in patients with R/R HL based on patient- and disease- related factors to develop individualized treatment plans

Agenda

Navigating Treatment Pathways in Relapsed/Refractory Hodgkin Lymphoma – John Sweetenham, MD, FRCP, FACP

Instructions for Participation and Credit

This activity is eligible for credit through August 23, 2018. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

John Sweetenham, MD, FRCP, FACP
Professor of Medicine
Executive Medical Director
Senior Director for Clinical Affairs
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah

Dr. John Sweetenham attended medical school at St. Bartholomew’s Hospital in London, and trained in oncology at the University of Southampton, UK, where he was subsequently a Senior Lecturer in Medical Oncology. He moved to the University of Colorado in 2000, joined the Cleveland Clinic Taussig Cancer Institute in 2005 as Vice Chairman for Clinical Research and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, and was Medical Director of the UCSD Nevada Cancer Institute from July 2012 until March 2013. Dr. Sweetenham is currently Professor of Medicine, Executive Medical Director, and Senior Director for Clinical Affairs at Huntsman Cancer Institute at the University of Utah.

Dr. Sweetenham is internationally renowned for his clinical research in malignant lymphomas and the use of stem cell transplantation and has authored more than 200 original articles, chapters, and books in this area of investigation. He has been principal investigator on national and international trials in lymphoma, and is a former core committee member of the Eastern Cooperative Oncology Group (ECOG) Lymphoma Committee and ECOG national principal investigator for studies in Hodgkin lymphoma. Dr. Sweetenham also serves as Chairman of the Clinical Trials Committee of Leukemia and Lymphoma Research, UK. In addition, he is on the editorial board of several journals, and was previously editor-in-chief of Hematological Oncology

Dr. Sweetenham has been listed in “Best Doctors in America” every year since 2003, Castle Connolly’s “America’s Top Doctors,” and “America’s Top Doctors for Cancer” every year since 2009, and has recently been acknowledged by “US News Top Doctors” and Angie’s List for Healthcare.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-17-158-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. John Sweetenham has received honoraria related to formal advisory activities, speakers’ bureau activities, and as a consultant from Seattle Genetics, Inc.

Planning Committee Disclosures

The individual listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Merck & Co., Inc., Seattle Genetics, and Takeda Oncology.

©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved